Skip to main content
  • Newer Prostate Cancer Agents Not Free of Heart Risk

    Patients with three or more cardiac conditions were at highest risk of early death

    An increased risk of early death was observed in advanced prostate cancer patients with a history of cardiovascular disease (CVD) starting on abiraterone acetate (Zytiga) or enzalutamide (Xtandi), a retrospective population-based study found.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details